Here are the members of HiveBio's first cohort for its life sciences accelerator program geared towards underrepresented ...

Despite its devastating impact, treatment options remain limited, highlighting the critical importance of advancing research efforts like those undertaken by Tiziana Life Sciences. Ivor Elrifi ...

LabCentral companies have raised more than $20 billion in funding and created more than 7,000 jobs in Massachusetts.

The randomized, double-blind, placebo-controlled trial aims to assess the safety, tolerability, and efficacy of intranasal foralumab in patients with na-SPMS, a form of multiple sclerosis (MS) ...

A group of Canadian undergrads is using plants to revolutionize medicine. Faced with soaring drug prices and global shortages ...

Tiziana Life Sciences (TLSA) announced dosing has commenced at Johns Hopkins University, JHU, Autoimmunity Center of Excellence, the third ...

A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS ...

The trial aims to evaluate the antibody’s efficacy in treating non-active secondary progressive multiple sclerosis.

[1],[2] About Tiziana Life Sciences Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are ...

1 Day TLSA -13.95% DJIA 0.08% Russell 2K -0.56% Health Care/Life Sciences 0.13% ...